Unknown

Dataset Information

Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma.


ABSTRACT:

Introduction

Pancreatic cancer is one of the deadliest solid organ cancers. In the absence of specific warning symptoms pancreatic cancer is diagnosed notoriously late. Current systemic chemotherapy regimens extend survival by a mere few months. With the advances in genetic, proteomic, and immunological profiling there is strong rationale to test kinase inhibitors to improve outcome.

Areas covered

This review article provides a comprehensive summary of approved treatments and past, present, and future developments of kinase inhibitors in pancreatic cancer. Emerging roles of protein kinase inhibitors are discussed in the context of the unique stroma, the lack of high-prevalence therapeutic targets and rapid emergence of acquired resistance, novel immuno-oncology kinase target

SUBMITTER: Rudloff U 

PROVIDER: S-EPMC9793333 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature